What does this research mean for the field?

Dysregulated alternative splicing contributes to the progression of diverse cardiomyopathies and represents a viable therapeutic target in heart failure. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review focuses on how alternative splicing contributes to heart failure and its progression.

June 29, 2026Current Cardiology ReportsOpen Access

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code

Q: What is the clinical evidence from this study?

Study design: Review. Population: Heart failure and cardiomyopathy. Intervention: Alternative splicing modulation.

View Full Paper

Ask AI

Bookmark

Key result

Dysregulated alternative splicing contributes to cardiomyopathy progression and offers a novel target for heart failure.

Why the study?

Heart failure remains a major cause of morbidity and mortality, but the underlying molecular mechanisms driving its progression at the level of alternative splicing require further review.

Design

Review

Authors

FAFrancisca AkhigbeUniversity of Cincinnati NSNingjing SongUniversity of Cincinnati JAJeyashree AlagarsamyBroad Center

Discussion

Member takes

Implication

Supports RNA-based splicing modulation as investigational in etiology-specific cardiomyopathies; hypothesis-generating and leaves open clinical translation.

Key Points

This review focuses on how alternative splicing contributes to heart failure and its progression.
Comprehensive overview of regulatory mechanisms involved in alternative splicing in the heart.
Emphasis on disease-specific splicing events in various forms of cardiomyopathy.
Discussion of recent advancements in targeting aberrant splicing for therapeutic strategies.
Alternative splicing is crucial for cardiac cell homeostasis and function.
Dysregulated splicing is linked to distinct types of cardiomyopathy, including dilated and ischemic forms.
Emerging RNA-based therapies show potential in modulating splicing to treat heart failure.

PICO

Population

Heart failure and cardiomyopathy

Intervention / Comparator

Alternative splicing modulation

This review provides a comprehensive overview of alternative splicing mechanisms in heart failure and highlights the potential of RNA-based strategies to modulate aberrant splicing as a therapeutic approach.

Limitations

Targeting RNA-binding proteins as a therapeutic strategy remains challenging due to their broad target specificity.
AAV-mediated gene delivery can alter total gene expression rather than selectively switching endogenous alternative splicing outcomes.

Cite This Study

Akhigbe et al. (2026) conducted a review in Heart failure and cardiomyopathy. Alternative splicing modulation was evaluated. Dysregulated alternative splicing contributes to the progression of various cardiomyopathies, presenting a novel therapeutic target for heart failure.

synapsesocial.com/papers/6a420adff91bb43ea91920c6 https://doi.org/10.1007/s11886-026-02386-0

View Full Paper

Ask AI

Bookmark

Implication

Supports RNA-based splicing modulation as investigational in etiology-specific cardiomyopathies; hypothesis-generating and leaves open clinical translation.

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Also Consider

Also Consider